Amplia Therapeutics inks collaboration with Eli Lilly to test narmafotinib plus KRAS G12C inhibitor in lung cancer

Amplia Therapeutics Ltd said it has entered into a clinical collaboration agreement with Eli Lilly and Company to study whether combining its lead oncology drug narmafotinib with Lilly’s next-generation KRAS G12C inhibitor can improve outcomes in lung cancer. The Australian-listed biotech, which also trades on the OTCQB market in the United States, framed the partnership around testing the combination in a clinical setting rather than limiting the effort to preclinical research.

Under the arrangement, the companies plan to evaluate narmafotinib alongside Lilly’s KRAS G12C program in lung cancer. KRAS is a gene that can drive cancer growth when mutated, and the “G12C” label refers to a specific mutation form. Lilly’s inhibitor is described in the announcement as its next-generation KRAS G12C treatment approach, but the companies did not provide additional product naming or regimen details in the material available for this report.

The collaboration centers on how the two therapies may work together, with narmafotinib serving as the partner asset and Lilly contributing the KRAS G12C inhibitor. Narmafotinib is identified as Amplia’s lead drug, and the agreement positions it as part of a combination strategy aimed at lung cancer patients whose tumors involve KRAS G12C alterations.

While the partnership indicates an ongoing effort to broaden treatment options in KRAS-driven disease, the announcement did not specify the trial design, such as whether the program is intended for first-line or later-line use, what patient criteria will be applied, or which endpoints will be used to gauge success. It also did not disclose the expected timing of patient enrollment, data readouts, or how the program will be structured across trial sites.

No financial terms were detailed in the available release. That includes whether Lilly will fund part of the study, how costs will be allocated, or whether Amplia would receive upfront payments, development milestones, or royalties tied to future sales. The absence of disclosure around economics and governance leaves investors and clinicians to look for additional filings or subsequent updates to clarify the commercial and operational stakes.

For Eli Lilly, the move fits a broader industry pattern of pairing targeted therapies with additional agents to deepen responses or delay resistance. For Amplia, the deal provides a pathway to test narmafotinib in combination with a validated class of targeted KRAS therapies that have become central to treatment strategies for a subset of lung cancer patients.

What is not yet clear is the specific phase of the trial or what the combination is expected to accomplish relative to current standards of care. Without those details, it is not possible to determine how quickly the companies could expect clinical indicates, or whether the trial is designed to establish efficacy, safety, or both. Further company statements and regulatory disclosures will likely be needed to fill in those gaps and to confirm the study’s scope.

Investors and the market will likely focus next on whether the companies release additional details on the clinical protocol, including the target population, dosing approach, and planned outcome measures. Updates on the timeline and on any interim or final results will be important for assessing whether the combination strategy gains traction in KRAS-mutant lung cancer.